Cargando…

Immune Response of a Heterologous mRNA-1273 Second-Dose Immunization after a First Dose of ChadOx1 against SARS-CoV-2: A Cross-Sectional Study

Heterologous vaccination regimens could contribute to broadening vaccination coverage. To date, there is little evidence on the effectiveness of a combination of adenoviral COVID-19 vaccines with a second dose of mRNA vaccines. This study aims to evaluate the antibody response to the SARS-CoV-2 spik...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albanesi, Beatrice, Godono, Alessandro, Comoretto, Rosanna Irene, Casabona, Elena, Curoso, Giuliano, Leone, Massimiliano Victor, Milanesio, Nicolò, Mirra, Ilenia, Montrucchio, Giulia, Pittaluga, Fabrizia, Cavallo, Rossana, Clari, Marco, Ciocan, Catalina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416710/ https://www.ncbi.nlm.nih.gov/pubmed/36016129 http://dx.doi.org/10.3390/vaccines10081241

Ejemplares similares

Choosing between Homologous or Heterologous COVID-19 Vaccination Regimens: A Cross-Sectional Study among the General Population in Italy
por: Clari, Marco, et al.
Publicado: (2022)

Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia
por: Gordon, Sally F., et al.
Publicado: (2021)

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
por: Sheng, Wang-Huei, et al.
Publicado: (2022)

A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19
por: Badier, Laure, et al.
Publicado: (2021)

Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination
por: Kaku, Chengzi I., et al.
Publicado: (2022)

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
por: Normark, Johan, et al.
Publicado: (2021)

Prolonged febrile illness following first dose of ChAdOx1
por: Caruana Dingli, Michael, et al.
Publicado: (2023)

Double high-dose immunoglobulin for ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia()
por: Huang, Ching-Tai, et al.
Publicado: (2021)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022)

Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan
por: Kang, Chun-Min, et al.
Publicado: (2022)

Humoral immune response to an mRNA-1273 booster after chAdOx1-nCoV-19-priming among patients undergoing hemodialysis
por: Cheng, Bo-Yu, et al.
Publicado: (2023)

Antibody Response Induced by Two Doses of ChAdOx1 nCoV-19, mRNA-1273, or BNT162b2 in Liver Transplant Recipients
por: Lim, So Yun, et al.
Publicado: (2022)

Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia
por: Holm, Sverre, et al.
Publicado: (2021)

Two flares of Still’s disease after two doses of the ChAdOx1 vaccine
por: Roongta, Rashmi, et al.
Publicado: (2022)

Immune Thrombocytopenia Following Booster Dose of the Moderna mRNA-1273 Vaccine
por: Breetz, Katherine A, et al.
Publicado: (2022)

Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine
por: Rogawski McQuade, Elizabeth T, et al.
Publicado: (2021)

Arterial thrombosis following first-dose ChAdOx1 vaccination: a case series
por: Chatterton, Sophie, et al.
Publicado: (2022)

Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain
por: Fernández-Ciriza, Leire, et al.
Publicado: (2022)

Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination
por: Rujkorakarn, P., et al.
Publicado: (2023)

Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP
por: Costa Clemens, Sue Ann, et al.
Publicado: (2022)

Resistance towards ChadOx1 nCoV-19 in an 83 Years Old Woman Experiencing Vaccine Induced Thrombosis with Thrombocytopenia Syndrome
por: Gillot, Constant, et al.
Publicado: (2022)

Immunoglobulin A Vasculitis Following ChadOx1 nCoV-19/AZD1222 (AstraZeneca COVID-19 Vaccine) Vaccination
por: Seo, Hyun-Min, et al.
Publicado: (2023)

Risk of Mortality from Respiratory Malignant and Non-Malignant Diseases among Talc Miners and Millers: A Systematic Review and Meta-Analysis
por: Ciocan, Catalina, et al.
Publicado: (2022)

Vaccination Confidence among Healthcare Workers: Results from Two Anamnestic Questionnaires Adopted in the COVID-19 and Influenza Campaign
por: Mansour, Ihab, et al.
Publicado: (2022)

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
por: Shrotri, Madhumita, et al.
Publicado: (2021)

Immunogenicity of ChAdOx1 (Covishield) Booster Dose in Healthcare Providers: A Pre-Post Study
por: Meher, Trupti, et al.
Publicado: (2023)

Humoral Immune Response of Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Prime-Boost Vaccination against SARS-CoV-2 Variants in Korea
por: Lim, Heeji, et al.
Publicado: (2023)

Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea
por: Jeon, Minji, et al.
Publicado: (2021)

Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose
por: Krzywicka, Katarzyna, et al.
Publicado: (2022)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
por: Berg, Adam, et al.
Publicado: (2021)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
por: Zhang, Cheng, et al.
Publicado: (2023)

Comment on “Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination”
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels
por: Alharbi, Naif Khalaf, et al.
Publicado: (2019)

AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice
por: Stebbings, Richard, et al.
Publicado: (2022)

Immunogenicity of Two Doses of ChAdOx1 nCoV-19 Vaccine in Lung Transplant Recipients
por: Carlier, F.M., et al.
Publicado: (2022)

Accelerated Hypertension and Intracerebral Haemorrhage Following First Dose of ChAdOx1-nCOV-19 Vaccination
por: Pandey, Shweta, et al.
Publicado: (2022)

Occupational asbestos exposure and urinary bladder cancer: a systematic review and meta-analysis
por: Franco, Nicolò, et al.
Publicado: (2023)

Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
por: Henze, Larissa, et al.
Publicado: (2023)

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ea2vq70qnasguh39dvg3gif9ji